Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.05 is 31% below its 1-year average of 0.07, near the low end of its 1-year range (0.00–0.22).
As of the fiscal period ended Tuesday, June 30, 2026. 48.27% below its 12-month average of 0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05.
DEBT TO EQUITY RATIO
0.05
DEBT TO EQUITY RATIO AVG TTM
0.09
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-48.27%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-58.78%
vs the sector median at left
Parabilis Medicines, Inc.
Market Cap
$3.36B
Debt to Equity Ratio
0.05
TTM Avg
0.09
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.38B
Debt to Equity Ratio
0.06
TTM Avg
0.06
3Y Avg
0.10
5Y Avg
0.10
Market Cap
$3.31B
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$3.44B
Debt to Equity Ratio
0.07
TTM Avg
0.08
3Y Avg
0.13
5Y Avg
0.24
Market Cap
$3.48B
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$3.52B
Debt to Equity Ratio
3.91
TTM Avg
6.45
3Y Avg
3.52
5Y Avg
2.47
Market Cap
$3.54B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.36B | 0.05 | 0.09 | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 0.06 | 0.06 | 0.10 | 0.10 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 0.01 | 0.00 | 0.00 | 0.00 |
| CareDx, Inc (CDNA)vs › | $3.30B | 0.05 | 0.08 | 0.10 | 0.08 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 0.07 | 0.08 | 0.13 | 0.24 |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | 1.40 | 0.83 | 0.59 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | 0.02 | 0.03 | 0.01 | 0.02 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 3.91 | 6.45 | 3.52 | 2.47 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 0.01 | 0.01 | 0.01 | 0.01 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 0.26 | 0.30 | 0.21 | 0.14 |
Debt/Equity
0.05
Current Ratio
17.91
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.05 |
| 2026-03-31 | 0.22 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
